Atomera Incorporated vs Nuwellis Inc — how do they compare? Atomera Incorporated trades at $5.55 (market cap $209.56M), while Nuwellis Inc trades at $1.5 (market cap $522.76K). The key difference: Atomera Incorporated is far larger — about 400.9× Nuwellis Inc's market cap, and Atomera Incorporated is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| ATOM | NUWE | |
|---|---|---|
Market Cap | $209.56M | $522.76K |
Sector | Technology | Technology |
52-Week High | $12.11 | $220.50 |
52-Week Low | $1.99 | $1.42 |
Enterprise Value | $172.37M | -$1.29M |
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →